207 related articles for article (PubMed ID: 16772814)
1. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
Lyons KE; Pahwa R
Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
[TBL] [Abstract][Full Text] [Related]
2. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Stathis P; Konitsiotis S; Tagaris G; Peterson D;
Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833
[TBL] [Abstract][Full Text] [Related]
4. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Tousi B; Subramanian T
Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
[No Abstract] [Full Text] [Related]
5. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
[No Abstract] [Full Text] [Related]
6. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Wong KK; Alty JE; Goy AG; Raghav S; Reutens DC; Kempster PA
Mov Disord; 2011 Jul; 26(8):1552-5. PubMed ID: 21538524
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in tardive dyskinesia.
Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
[TBL] [Abstract][Full Text] [Related]
8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
9. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam in tardive dyskinesia: an open label study.
Konitsiotis S; Pappa S; Mantas C; Mavreas V
Mov Disord; 2006 Aug; 21(8):1219-21. PubMed ID: 16637037
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
12. Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia.
Kim HJ; Lee JY; Kim JY; Kim DG; Paek SH; Jeon BS
Clin Neurol Neurosurg; 2008 Apr; 110(4):328-32. PubMed ID: 18164541
[TBL] [Abstract][Full Text] [Related]
13. Levodopa unresponsive symptoms in Parkinson disease.
Sethi K
Mov Disord; 2008; 23 Suppl 3():S521-33. PubMed ID: 18781679
[TBL] [Abstract][Full Text] [Related]
14. Blink reflex in Parkinson's disease with levodopa-induced dyskinesia.
Iriarte LM; Chacon J; Madrazo J; Chaparro P
Funct Neurol; 1989; 4(3):257-61. PubMed ID: 2792861
[TBL] [Abstract][Full Text] [Related]
15. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
Nutt JG; Carter JH; Carlson NE
Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson's Disease: A Systematic Review.
Ebada MA; Alkanj S; Ebada M; Abdelkarim AH; Diab A; Aziz MAE; Soliman AM; Fayed N; Bahbah EI; Negida A
CNS Neurol Disord Drug Targets; 2019; 18(4):317-325. PubMed ID: 30868968
[TBL] [Abstract][Full Text] [Related]
19. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
De Reuck J; De Weweire M; Van Maele G; Santens P
J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
[TBL] [Abstract][Full Text] [Related]
20. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
